VIPoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
Madhu Sigdel (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{VIPoma}} | {{VIPoma}} | ||
{{CMG}}{{AE}}{{MSI}}{{PSD}} | {{CMG}}{{AE}}{{MSI}}{{PSD}}{{Homa}} | ||
==Overview== | ==Overview== | ||
If left untreated, patients with VIPoma may progress to develop | If left untreated, [[patients]] with VIPoma may progress to [[Development|develop]] [[watery diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]]. Common [[complications]] of VIPoma include [[metastasis]], [[cardiac arrest]] from [[low blood potassium]] level, and [[dehydration]]. The presence of [[metastasis]] is associated with a particularly poor [[prognosis]] among [[patients]] with VIPoma, with a 5 year [[survival rate]] of 60%. | ||
==Natural History== | ==Natural History== | ||
*If left untreated, patients with VIPoma may progress to develop | *If left untreated, [[patients]] with VIPoma may progress to [[Development|develop]] [[watery diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]].<ref name="NatanziAmini2009">{{cite journal|last1=Natanzi|first1=Naveed|last2=Amini|first2=Mazyar|last3=Yamini|first3=David|last4=Nielsen|first4=Shawn|last5=Ram|first5=Ramin|title=Vasoactive Intestinal Peptide Tumor|journal=Scholarly Research Exchange|volume=2009|year=2009|pages=1–7|issn=1687-8299|doi=10.3814/2009/938325}}</ref> | ||
*VIPoma have a very slow growth rate compared to most malignant tumors. | *VIPoma have a very slow [[growth]] rate compared to the most [[malignant tumors]]. | ||
==Complications== | ==Complications== | ||
Common complications of VIPoma include: | Common [[complications]] of VIPoma include:<ref>{{Cite journal | ||
| author = [[J. V. VERNER]] & [[A. B. MORRISON]] | |||
| title = Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia | |||
| journal = [[The American journal of medicine]] | |||
| volume = 25 | |||
| issue = 3 | |||
| pages = 374–380 | |||
| year = 1958 | |||
| month = September | |||
| doi = 10.1016/0002-9343(58)90075-5 | |||
| pmid = 13571250 | |||
}}</ref><ref>{{Cite journal | |||
| author = [[A. Ayub]], [[M. Zafar]], [[A. Abdulkareem]], [[M. A. Ali]], [[T. Lingawi]] & [[A. Harbi]] | |||
| title = Primary hepatic vipoma | |||
| journal = [[The American journal of gastroenterology]] | |||
| volume = 88 | |||
| issue = 6 | |||
| pages = 958–961 | |||
| year = 1993 | |||
| month = June | |||
| pmid = 8389095 | |||
}}</ref> | |||
* [[Metastasis]] | * [[Metastasis]] | ||
* [[Cardiac arrest]] from low blood | * [[Cardiac arrest]] from [[low blood potassium]] level | ||
* [[Dehydration]] | * [[Dehydration]] | ||
==Prognosis== | ==Prognosis== | ||
*Surgery can usually cure VIPomas. However, in one-third to one-half of patients, the tumor has spread by the time of diagnosis and cannot be cured | *[[Surgery]] can usually [[cure]] VIPomas. However, in one-third to one-half of [[patients]], the [[tumor]] has [[Spread of the cancer|spread]] by the time of [[diagnosis]] and cannot be [[Cure|cured]].<ref name="pmid27583474">{{cite journal| author=Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E| title=Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report. | journal=J Clin Endocrinol Metab | year= 2016 | volume= 101 | issue= 10 | pages= 3564-3567 | pmid=27583474 | doi=10.1210/jc.2016-2051 | pmc=5052354 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27583474 }}</ref> | ||
*The 5-year [[Survival rate|survival]] for [[patients]] with localized VIPoma is 94% whereas [[metastatic]] [[pancreatic]] VIPomas is 60%, respectively. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Endocrinology]] | |||
[[Category:Gastroenterology]] | |||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of VIPoma natural history, complications and prognosis |
|
VIPoma natural history, complications and prognosis in the news |
|
Blogs on VIPoma natural history, complications and prognosis |
|
Risk calculators and risk factors for VIPoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy. Common complications of VIPoma include metastasis, cardiac arrest from low blood potassium level, and dehydration. The presence of metastasis is associated with a particularly poor prognosis among patients with VIPoma, with a 5 year survival rate of 60%.
Natural History
- If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy.[1]
- VIPoma have a very slow growth rate compared to the most malignant tumors.
Complications
Common complications of VIPoma include:[2][3]
- Metastasis
- Cardiac arrest from low blood potassium level
- Dehydration
Prognosis
- Surgery can usually cure VIPomas. However, in one-third to one-half of patients, the tumor has spread by the time of diagnosis and cannot be cured.[4]
- The 5-year survival for patients with localized VIPoma is 94% whereas metastatic pancreatic VIPomas is 60%, respectively.
References
- ↑ Natanzi, Naveed; Amini, Mazyar; Yamini, David; Nielsen, Shawn; Ram, Ramin (2009). "Vasoactive Intestinal Peptide Tumor". Scholarly Research Exchange. 2009: 1–7. doi:10.3814/2009/938325. ISSN 1687-8299.
- ↑ J. V. VERNER & A. B. MORRISON (1958). "Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia". The American journal of medicine. 25 (3): 374–380. doi:10.1016/0002-9343(58)90075-5. PMID 13571250. Unknown parameter
|month=ignored (help) - ↑ A. Ayub, M. Zafar, A. Abdulkareem, M. A. Ali, T. Lingawi & A. Harbi (1993). "Primary hepatic vipoma". The American journal of gastroenterology. 88 (6): 958–961. PMID 8389095. Unknown parameter
|month=ignored (help) - ↑ Nilubol N, Freedman EM, Quezado MM, Patel D, Kebebew E (2016). "Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report". J Clin Endocrinol Metab. 101 (10): 3564–3567. doi:10.1210/jc.2016-2051. PMC 5052354. PMID 27583474.